Cargando…
索拉非尼单药治疗FLT3-ITD突变阳性急性髓系白血病14例疗效及安全性分析
OBJECTIVE: To explore the efficacy and safety of Sorafenib as monotherapy to FLT3 positive acute myeloid leukemia (AML). METHODS: From April 2014 to December 2015, fourteen AML patients with FLT3 positive, 7 males and 7 females with a median age of 42 (range: 14–81) years old, were enrolled in this...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348496/ https://www.ncbi.nlm.nih.gov/pubmed/28088962 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.12.002 |
Ejemplares similares
-
索拉非尼联合CHAG方案诱导治疗10例FLT3-ITD突变阳性急性髓系白血病患者疗效观察
Publicado: (2016) -
索拉非尼联合化疗一线治疗FLT3-ITD突变阳性急性髓系白血病的临床对照研究
Publicado: (2017) -
索拉非尼联合化疗治疗FLT3-ITD突变阳性急性髓系白血病九例报告并文献复习
Publicado: (2015) -
索拉非尼联合维奈克拉、阿扎胞苷方案诱导治疗FLT3-ITD突变阳性急性髓系白血病12例的疗效及安全性分析
Publicado: (2022) -
索拉非尼作为挽救性治疗在难治复发性FLT3突变阳性急性髓系白血病中的临床应用研究
Publicado: (2016)